![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
BM Foxwell, A Mackie, V Ling and B Ryffel
Preclinical Research, Sandoz Ltd., Basle, Switzerland.
The immunosuppressive agent cyclosporine A has been shown to reverse multidrug resistance (MDR) in malignant cells. In the present study, a 3H-cyclosporine diazirine analogue was used to photolabel viable MDR Chinese hamster ovary cells. The 170-kDa membrane P-glycoprotein, which functions as a drug efflux pump, was strongly labeled. The binding of 3H-cyclosporine diazirine analogue to P-glycoprotein was competable by excess cyclosporine A and by the nonimmunosuppressive cyclosporine H. These results suggest that cyclosporine reverses the MDR phenotype by binding directly to P-glycoprotein and that this binding is not dependent on the immunosuppressive potential of the cyclosporine derivative. The identification of P-glycoprotein as a cyclosporine binding protein has obvious implications for cancer chemotherapy.
This article has been cited by other articles:
|
|
 |
|
  C. S. Gavigan, M. Shen, S. G. Machado, and A. Bell Influence of the Plasmodium falciparum P-glycoprotein homologue 1 (pfmdr1 gene product) on the antimalarial action of cyclosporin J. Antimicrob. Chemother., February 1, 2007; 59(2): 197 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Chester, S. P. Joel, S. L. Cheeseman, G. D. Hall, M. S. Braun, J. Perry, T. Davis, C. J. Button, and M. T. Seymour Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer J. Clin. Oncol., March 15, 2003; 21(6): 1125 - 1132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garrigues, N. Loiseau, M. Delaforge, J. Ferte, M. Garrigos, F. Andre, and S. Orlowski Characterization of Two Pharmacophores on the Multidrug Transporter P-Glycoprotein Mol. Pharmacol., December 1, 2002; 62(6): 1288 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Wada, M. Niimi, K. Niimi, A. R. Holmes, B. C. Monk, R. D. Cannon, and Y. Uehara Candida glabrata ATP-binding Cassette Transporters Cdr1p and Pdh1p Expressed in a Saccharomyces cerevisiae Strain Deficient in Membrane Transporters Show Phosphorylation-dependent Pumping Properties J. Biol. Chem., November 22, 2002; 277(48): 46809 - 46821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Yang, A. D. Vassil, and W. N. Hait Activation of Phospholipase C Induces the Expression of the Multidrug Resistance (MDR1) Gene through the Raf-MAPK Pathway Mol. Pharmacol., October 1, 2001; 60(4): 674 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baekelandt, G. Lehne, C. G. Trope, I. Szanto, P. Pfeiffer, B. Gustavssson, and G. B. Kristensen Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer J. Clin. Oncol., June 15, 2001; 19(12): 2983 - 2993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lu, F. Leonessa, R. Clarke, and I. W. Wainer Competitive and Allosteric Interactions in Ligand Binding to P-glycoprotein as Observed on an Immobilized P-glycoprotein Liquid Chromatographic Stationary Phase Mol. Pharmacol., January 1, 2001; 59(1): 62 - 68. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. E. Cardenas, M. C. Cruz, M. Del Poeta, N. Chung, J. R. Perfect, and J. Heitman Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System To Study Drug Action Clin. Microbiol. Rev., October 1, 1999; 12(4): 583 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chen and G. M. Pollack Altered Disposition and Antinociception of [D-Penicillamine2,5] Enkephalin in mdr1a-Gene-Deficient Mice J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 545 - 552. [Abstract] [Full Text]
|
|
|
|
|
|
S. Desrayaud, E. C. M. De Lange, M. Lemaire, A. Bruelisauer, A. G. De Boer, and D. D. Breimer Effect of the Mdr1a P-Glycoprotein Gene Disruption on the Tissue Distribution of SDZ PSC 833, a Multidrug Resistance-Reversing Agent, in Mice J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 438 - 443. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. E. Perkins, T. W. Wu, and S. M. Le Blancq Cyclosporin Analogs Inhibit In Vitro Growth of Cryptosporidium parvum Antimicrob. Agents Chemother., April 1, 1998; 42(4): 843 - 848. [Abstract] [Full Text]
|
|
|
|
|
|
A. Demmer, H. Thole, P. Kubesch, T. Brandt, M. Raida, R. Fislage, and B. Tummler Localization of the Iodomycin Binding Site in Hamster P-glycoprotein J. Biol. Chem., August 15, 1997; 272(33): 20913 - 20919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Demeule, R. M. Wenger, and R. Beliveau Molecular Interactions of Cyclosporin A with P-glycoprotein. PHOTOLABELING WITH CYCLOSPORIN DERIVATIVES J. Biol. Chem., March 7, 1997; 272(10): 6647 - 6652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Hemenway and J. Heitman Immunosuppressant Target Protein FKBP12 Is Required for P-Glycoprotein Function in Yeast J. Biol. Chem., August 2, 1996; 271(31): 18527 - 18534. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
